PAI-1 – Plasminogen Activator Inhibitor type 1 Polyclonal Antibody – HRP Conjugated
Affinity’s PAI-1 – Plasminogen Activator Inhibitor type 1 Polyclonal Antibody – HRP Conjugated is the base level of our horseradish peroxidase conjugated PAI-1 – Plasminogen Activator Inhibitor type 1 antibodies. The purity of IgG is typically 90% and is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v). The titre is essentially the same as the starting antiserum and each vial typically contains the amount of IgG recovered from one milliliter of antiserum however this IgG has been conjugated with Horseradish Peroxidase as an enzyme reporter. This PAI-1 – Plasminogen Activator Inhibitor type 1 Polyclonal Antibody – HRP Conjugated is generally intended for use as labeled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAPAI-HRP
Retail Product Size: 0.2mg vial
Host Animal: Sheep Anti-Human PAI-1 – Plasminogen Activator Inhibitor type 1 Polyclonal Antibody – HRP Conjugated
Species Cross Reactivity: View Chart
Description of PAI-1 (Type-1 Plasminogen Activator Inhibitor)
Type I plasminogen activator inhibitor, PAI-1, is a 50 kDa single-chain glycoprotein which belongs to the serine protease inhibitor (SERPIN) family of proteins. The concentration of PAI-1 in normal human plasma is very low, with an average concentration of approximately 20 ng/ml. The plasma concentrations of PAI-1 can be affected by a number of factors including diurnal variations, age, sex, pregnancy, obesity and exercise status. PAI-1 is synthesized by various cell types including endothelial cells, hepatocytes, vascular smooth muscle cells, fibroblasts, mesothelial cells, granulosa cells and malignant cell lines. It is also found in the α-granules of platelets as well as plasma. PAI-1 exists in at least three different conformations, including an active form with a half-life of approximately 1 – 3 hours, a latent form and a proteolytically or oxidatively inactivated form. The plasma glycoprotein vitronectin has been shown to bind active PAI-1 and stabilize it in its active conformation, extending its functional half-life to greater than 24 hours. Little specific binding of the latent or inactive forms of PAI-1 to vitronectin occurs. PAI-1 is considered to be the primary regulator of plasminogen activation in vivo. It is the major physiologic inhibitor of both the single chain and two-chain forms of tPA, being able to inhibit the single-chain form at least 10000 times greater than other PAIs.1-3
References and Reviews
- Kruithof, E.K.O. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis, 2:59-70, 1988.
- Edelberg, J.M, Sane, D.C., and Pizzo, S.V. Vascular regulation of plasminogen activator inhibitor-1 activity. Semin. Thromb. Hemost., 20(4):319-323, 1994.
- Loskutoff, D.J., Sawdey, M., and Mimuro, J. Type 1 plasminogen activator inhibitor, Prog. Thromb. Haemost., 9:87-115, 1988.